Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-300 phase 1 tarlatamab study in small cell lung cancer
NL-OMON59612Phase 1Completed
- Sponsor
- Amgen
- Start
- May 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoints: Primary endpoint(s) and Safety and tolerability. Started May 2019; status: completed.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON59612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59612.